Holcombsargent3082

Heel blood sampling of newborns plays an important role in the diagnosis of neonatal hypothyroidism, phenylketonuria, and other inherited metabolic diseases. Embracing breast milk sucking (EBMS) can increase the newborn's sense of security and can relieve pain. The purpose of the present study was to explore the effect of EBMS on alleviating the pain of neonatal heel blood sampling.

A total of 96 neonates undergoing heel blood screening were selected from June 2019 to June 2020, and were randomly divided into 2 groups (n=48 in each group). The control group was given routine intervention, and the observation group was given EBMS intervention. The success rate and time-consuming of 1-time blood collection, heel congestion after blood collection, crying time and bleeding time of newborns, blood oxygen saturation and heart rate index, and pain were compared between the 2 groups.

The success rate of 1-time blood collection in the observation group was higher than that in the control group, and the blood colood oxygen saturation and heart rate are at normal values; and effectively reduce the occurrence of heel congestion after blood collection, crying time and bleeding time of newborn heel blood collection, and neonatal pain.

At present, the recommendation grade of transcatheter aortic valve implantation (TAVI) for aortic valve stenosis (AVS) has increased in many guidelines. Establishing an optimized TAVI nurse team is essential for improving surgical quality and outcomes. We compared the professional requirements for nurses in two surgical approaches for aortic stenosis and the different roles of nurses in the surgical teams, with an attempt to further improve the training programs for specialized nurses.

The required professional knowledge and the role of nursing staff during TAVI or AVR (Conventional aortic valve replacement) were analyzed. These included knowledge on the pathophysiology of aortic stenosis, advantages and disadvantages of different heart valves, extracorporeal circulation, nursing cooperation during valve replacement, conventional surgical instruments and interventional consumables, surgical complications, radiation protection, operation of pacemakers, theory and operation of electric defibrillation. And tal training for future cardiac operation.

To explore the role of intestinal flora in seborrhea, non-targeted metabolomics analysis was carried out.

Fecal samples were collected from 5 seborrheic patients and 5 healthy controls from October 2019 to April 2020. ChlorogenicAcid Ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS) was used to detect metabolic fingerprinting in feces samples, and high-throughput sequencing and bioinformatic analysis of 16S rRNA for intestinal flora. The variable importance in projection (VIP) values of orthogonal partial least squares-discriminant analysis (OPLS-DA) and P values of univariate statistical analysis were used to determine the differential metabolites between the seborrhea group and the control group. The interaction between flora and metabolites was analyzed using several approaches.

A total of 45 metabolites with significantly different intensities were found between the seborrhea group and the healthy control group. A positive correlation between flora and metabolites was found in 57 pairs and a negative correlation was found in 104 pairs. In addition, 11 metabolic pathways were significantly altered, including 4 amino acid metabolic pathways, 2 bile acid metabolic pathways, and 2 basic metabolic signaling pathways (ABC transporters pathway and mTOR signaling pathway). Central carbon metabolism in cancer, glutathione metabolism, protein digestion and absorption were also involved.

The occurrence of seborrhea may be related to changes in intestinal flora and metabolic pathways. There is a close association between seborrhea and amino acid metabolic pathways or ABC transporters.

The occurrence of seborrhea may be related to changes in intestinal flora and metabolic pathways. There is a close association between seborrhea and amino acid metabolic pathways or ABC transporters.Lung cancer is a malignancy with the highest morbidity and mortality in the world. Radiotherapy, chemotherapy, targeted therapy, and immunotherapy have been widely used to treat metastatic non-small cell lung cancer (NSCLC). Stereotactic body radiotherapy (SBRT), also known as stereotactic ablation radiotherapy (SABR), can precisely deliver a high dose of radiation to a target in a limited area. SBRT has been established as the standard treatment for patients with early NSCLC who are unsuitable for operation or refuse surgery and patients with oligometastatic NSCLC who are not suitable for surgery. As an immunologic agent, pembrolizumab has been approved to treat metastatic NSCLC in certain countries, including China and the United States. Increased tumor proportion score (TPS) can reduce pembrolizumab's immunotherapeutic effect, while SBRT can reduce TPS and enhance immunotherapy efficacy. However, there have been no reports in China on metastatic NSCLC patients who have received pembrolizumab monotherapy after stereotactic body radiotherapy (SBRT). Here, we present a case of progression-free survival (PFS) of nearly 5 years with pembrolizumab monotherapy after SBRT for metastatic NSCLC. This case is the patient with the most prolonged medication duration and who experienced the most efficacious treatment among the patients with metastatic NSCLC reported in the Chinese literature.Gastrointestinal stromal tumor (GIST) is the most common type of gastrointestinal mesenchymal tumor. Fewer than 2% of patients with metastatic GIST treated with imatinib experience a pathologic complete response. Furthermore, response to imatinib and subsequent-line tyrosine kinase inhibitor is limited by most patients developing drug resistance; median time to progression is 2 years for imatinib, and about half a year for sunitinib and regorafenib. In recent years, ripretinib, a fourth-line medicine, is been of the most important advances in the treatment of GIST. The ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS) a double-blind, randomised, placebo-controlled, phase 3 trial study showed that ripretinib can significantly reduce the risk of disease progression and mortality in patients with advanced GIST ≥4 lines, and has obvious clinical activity for a variety of KIT/platelet-derived growth factor receptor α (PDGFR α) gene mutations. This paper presents a case of advanced rectal GIST treated with ripretinib in China.